CDKN2A and Lynch syndrome: Peters et al. [31] evaluated surveillance strategies of MRI (one time, every 5 years, every 2 years, and annually) with follow-up EUS for eight separate high risk groups (BRCA1 and BRCA2, PALB2, ATM, Lynch syndrome, TP53, CDKN2A, and STK11) and varied their starting ages (40–70 years old).